Table 1. Baseline characteristics of the evaluated cohort.
| Characteristics | Patients with disease control, n (%) | Patients with progressive disease, n (%) | P value |
|---|---|---|---|
| Number of patients | 9 (39.1) | 14 (60.9) | |
| ECOG performance status | |||
| 0–1 | 7 (77.8) | 9 (64.2) | 0.515 |
| 2 | 2 (22.2) | 5 (35.8) | |
| Sex | |||
| Male | 4 (44.4) | 8 (57.1) | 0.573 |
| Female | 5 (55.6) | 6 (42.9) | |
| Age (years) | |||
| Median [range] | 66 [47–77] | 58 [37–79] | 0.280 |
| Smoking status | |||
| Never-smoker | 3 (33.3) | 1 (7.1) | 0.271 |
| Smoker | 6 (66.7) | 13 (92.9) | |
| Histology | |||
| Adenocarcinoma | 7 (77.8) | 10 (71.4) | |
| Squamous | 1 (11.1) | 4 (28.6) | 0.402 |
| Mixed | 1 (11.1) | 0 (0) | |
| PD-L1 status | |||
| >50% | 1 (11.1) | 1 (7.1) | 0.818 |
| <1% | 2 (22.2) | 2 (14.3) | |
| Not assessed | 6 (66.6) | 11 (78.6) | |
| EGFR mutation positive | 0 (0) | 0 (0) | |
| Treatment | |||
| Nivolumab | 8 (88.9) | 13 (92.8) | 0.535 |
| Pembrolizumab | 1 (11.1) | 1 (7.2) |
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PD-L1, programmed death protein-ligand 1.